New Hope for AUD: Novel Drug Trial Targets Brain's Reward System

BOSTON, MA – April 29, 2026 – Newleos Therapeutics, a clinical-stage biotech company, has initiated a pivotal clinical trial that could represent a significant turning point in the treatment of Alcohol Use Disorder (AUD). The company announced today it has dosed the first participant in its Phase 1b study of NTX-2001, a novel drug designed to modulate the brain's reward pathways and reduce alcohol consumption.

The study, conducted in collaboration with the prestigious Yale School of Medicine, marks the first time a drug of this class—a partial agonist of the trace amine-associated receptor 1 (TAAR1)—has been clinically evaluated for AUD. For the nearly 30 million Americans affected by this disorder and a medical community starved for innovation, the trial represents a glimmer of hope in a field that has seen little progress in decades.

A Stagnant Landscape and an Urgent Need

Alcohol Use Disorder is a devastating public health crisis. It is one of the leading preventable causes of death in the United States, contributing to over 95,000 deaths annually. Characterized by compulsive alcohol consumption despite severe life-threatening consequences, the disorder wreaks havoc on individuals, families, and society. Yet, despite its prevalence, treatment options remain strikingly limited.

“With the last drug approval for alcohol use disorder nearly two decades ago, the urgency for novel, efficacious pharmacotherapeutic interventions could not be greater,” noted Stephanie O’Malley, Ph.D., a clinical advisor to Newleos.

Currently, only three medications are approved by the U.S. Food and Drug Administration (FDA) for AUD: disulfiram, naltrexone, and acamprosate. Each has limitations. Disulfiram works by inducing a severe negative reaction to alcohol, a mechanism reliant on deterrence. Naltrexone, an opioid antagonist, helps reduce the rewarding effects of alcohol, while acamprosate is thought to reduce cravings through a different neural pathway. While these drugs can be effective for some, their overall efficacy is modest, and their use is not widespread. Shockingly, fewer than 10 percent of individuals with AUD receive any form of treatment, and an even smaller fraction are prescribed one of these medications. This treatment gap underscores the desperate need for new, more effective, and better-tolerated therapies.

A Novel Approach: Targeting the Brain's Reward System

Newleos' NTX-2001 aims to tackle the problem from a new angle by targeting the neurobiology of addiction itself. The drug is a selective partial agonist of TAAR1, a receptor found in key brain regions that regulate the dopamine system—the brain's central hub for reward, motivation, and reinforcement.

In addiction, the dopamine system becomes dysregulated, leading to intense cravings and compulsive behavior. NTX-2001 is designed to act as a "normalizer." By partially activating the TAAR1 receptor, it is believed to modulate dopamine signaling in a state-dependent manner, dampening the excessive dopamine release that reinforces drinking behavior without completely shutting the system down.

“TAAR1 partial agonists are well-suited as potential treatments for alcohol use disorder by modulating reward pathways in the brain,” commented Federico Bolognani, M.D., Ph.D., Newleos’ Co-founder and Chief Medical Officer. He explained that early signs of efficacy would provide crucial clinical support for the mechanism. “Because addiction almost always involves dopamine dysregulation, success in this Phase 1b study would also be a critical first step in the development of a drug that could treat a wider array of addictive disorders.”

This approach is a significant departure from existing treatments and represents a potential first-in-class therapy for AUD. If successful, it could not only provide a new tool for AUD but also validate a therapeutic strategy applicable to other substance use disorders involving similar dopamine pathway disruptions.

From Schizophrenia to Substance Use: The Journey of NTX-2001

The path of NTX-2001 to this pioneering AUD trial is a testament to modern biotech strategy. The compound, also known as ralmitaront, was not originally developed for addiction. It was part of a pipeline at the pharmaceutical giant Roche, where it was advanced into a Phase II study as a potential treatment for schizophrenia and schizoaffective disorder.

However, in 2023, Roche terminated that trial after an interim analysis suggested the drug was unlikely to meet its primary endpoint. While a setback for its use in psychosis, the story did not end there. Newleos Therapeutics, which launched in 2025, licensed the compound along with a portfolio of other clinical-stage assets from Roche. The Boston-based startup saw a different potential for NTX-2001, repurposing it to target the underlying mechanisms of addiction.

This strategy, while not without risk, is built on a solid foundation of safety data. Before the current AUD trial, NTX-2001 had already been studied in eight clinical trials involving approximately 645 participants. Across these studies, the drug was consistently found to be safe and well-tolerated, de-risking a significant part of the early development process and allowing Newleos to move directly into a proof-of-concept study for its new indication.

The Biotech Bet: A Well-Funded Push into Addiction Medicine

The ambitious effort to bring NTX-2001 forward is backed by serious financial and scientific muscle. Newleos Therapeutics launched with an oversubscribed $93.5 million Series A financing round led by Goldman Sachs Alternatives, with participation from other major life science investors including Novo Holdings A/S and Longwood Fund.

This substantial investment reflects a growing recognition among investors of the vast unmet need—and market opportunity—in neuropsychiatry, a notoriously difficult area for drug development. Newleos' model of in-licensing de-risked assets from large pharmaceutical companies and applying them to new indications with high unmet needs is a calculated bet that is gaining traction in the industry.

The collaboration with Yale School of Medicine further bolsters the program's credibility. The Phase 1b study (NCT07520292) is actively recruiting at Yale's New Haven campus, leveraging the institution's deep expertise in addiction science and clinical research.

The Road Ahead: A Closer Look at the Clinical Trial

The Phase 1b study is a randomized, double-blind, placebo-controlled trial, the gold standard for clinical research. It will enroll adults aged 21 to 60 with a current diagnosis of AUD. For approximately two weeks, participants will receive either NTX-2001 or a placebo once daily.

The trial's primary goal is to see if the drug can reduce alcohol consumption. This will be measured using an established human laboratory model known as the alcohol drinking paradigm (ADP), which simulates real-world drinking behavior in a controlled setting. Researchers will also closely monitor safety, tolerability, and how the drug moves through the body.

"As the first time a TAAR1 partial agonist has been evaluated in the clinic for alcohol use disorder, this study of NTX-2001 represents an important milestone for Newleos and for the field of addiction medicine," Dr. Bolognani stated. The results of this small but critical study will be eagerly awaited by patients, clinicians, and researchers, offering the first clinical test of a promising new strategy against an old and relentless disease.